GLUE Competitors & Alternatives
Compare Monte Rosa Therapeutics Inc with similar stocks in the same industry
Biotechnology
GLUE
Main Stock$18.50
Tradestie Score
54
Market Cap
$463.20M
Revenue Growth
-1.0%
Analyst Upside
+74.8%
Top Competitors
228 stocks in Biotechnology| Company | Price | Market Cap | P/E | Score | Action |
|---|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics, Inc. Common Stock
|
$32.34
|
$1.63B | - | 58 | Compare |
|
BHVN
Biohaven Ltd.
|
$8.76
|
$1.57B | - | 57 | Compare |
|
VCEL
Vericel Corporation
|
$34.74
|
$1.56B | 77.0 | 58 | Compare |
|
DNTH
Dianthus Therapeutics, Inc. Common Stock
|
$82.98
|
$1.55B | - | 58 | Compare |
|
HRMY
Harmony Biosciences Holdings, Inc. Common Stock
|
$30.24
|
$1.55B | 12.4 | 60 | Compare |
|
PHVS
Pharvaris N.V. Ordinary Shares
|
$29.77
|
$1.55B | - | 61 | Compare |
|
NVAX
Novavax Inc
|
$9.18
|
$1.54B | - | 58 | Compare |
|
AUPH
Aurinia Pharmaceuticals Inc
|
$15.55
|
$1.50B | 7.1 | 59 | Compare |
|
GPCR
Structure Therapeutics Inc. American Depositary Shares
|
$37.37
|
$1.50B | - | 56 | Compare |
|
AMLX
Amylyx Pharmaceuticals, Inc. Common Stock
|
$13.11
|
$1.49B | - | 46 | Compare |
More GLUE Analysis
Data updated: May 18, 2026 | Industry: Biotechnology (SIC 2836)
228 stocks in this industry